第一医药上半年实现营收9.97亿元 同比增长11.58%

Core Viewpoint - The company reported a mixed performance in the first half of 2025, with revenue growth but a significant decline in net profit due to previous year's compensation payments [1] Financial Performance - The company achieved operating revenue of 999.7 million yuan, a year-on-year increase of 11.58% [1] - Net profit attributable to shareholders was 14.02 million yuan, a year-on-year decrease of 89.19% [1] - The company's net profit excluding non-recurring items was 9.01 million yuan, a year-on-year increase of 24.58% [1] Business Development - The company expanded its retail network, increasing the number of retail stores to 208, with over 10 new pet specialty stores added [2] - The first pet-friendly pharmacy in Shanghai was recognized by the Shanghai Commercial Association [2] - The company added 14 new medical insurance stores, raising the proportion of direct medical insurance stores to 75.30%, an increase of 7.64 percentage points from the previous year [2] - Online business grew by 38.5%, with O2O business increasing by 46.1% [2] - Cross-border sales of health products through its subsidiary in Hong Kong saw a 12.4% increase [2] Supply Chain Optimization - The company optimized procurement costs and strengthened non-pharmaceutical supply chain construction, with self-owned brand sales increasing by 67.4% [3] - The company established a private equity investment fund focusing on functional food sectors [3] Industry Trends - The retail pharmacy industry is experiencing an accelerated closure trend, with 39,228 stores expected to close in 2024, a closure rate of approximately 5.76% [3] - The industry is shifting from expansion to enhancing profitability through refined operations [4]